Alder Biopharmaceuticals, Inc.
(NASDAQ : ALDR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-1.22%194.331.3%$535.10m
GILDGilead Sciences, Inc.
-0.44%65.880.9%$358.45m
ALXNAlexion Pharmaceuticals, Inc.
-4.12%103.382.0%$312.11m
ILMNIllumina, Inc.
0.98%301.193.5%$306.20m
BIIBBiogen Inc.
-1.60%234.891.3%$294.92m
CELGCelgene Corporation
0.10%98.701.3%$288.66m
AAgilent Technologies, Inc.
0.60%76.861.6%$174.39m
SRPTSarepta Therapeutics, Inc.
-2.82%82.4914.6%$173.82m
VRTXVertex Pharmaceuticals Incorporated
-1.19%173.911.9%$172.47m
REGNRegeneron Pharmaceuticals, Inc.
-2.03%282.262.6%$169.09m
EXASExact Sciences Corporation
-1.68%105.0824.1%$132.93m
ACADACADIA Pharmaceuticals Inc.
-3.42%41.1513.9%$111.06m
INCYIncyte Corporation
-1.56%77.872.5%$84.38m
BMRNBioMarin Pharmaceutical Inc.
0.00%75.004.3%$71.23m
ALDRAlder Biopharmaceuticals, Inc.
0.70%18.8310.2%$64.38m

Company Profile

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.